All In Biotech

Drug Trial Radar · NCT06584058

HPP737 Substance Balance Study in Human

[14C] A Single-center, Nonrandomized, Open, Single-dose Substance Balance Study of HPP737 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

8

Planned (sponsor's estimate)

Start

Aug 30, 2024

Primary completion

Jul 30, 2025

Study completion Aug 30, 2025

Sponsor

Lead sponsor
Newsoara Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Sep 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Main research purpose 1. Quantitative analysis of the total amount of radioactivity in excreta (urine and feces) of male healthy subjects after oral administration of \[14C\]HPP737, to obtain the cumulative excretion rate and main excretion routes of human radioactivity; 2. To identify the main metabolites in the offspring of \[14C\]HPP737 in healthy male subjects, and to determine the main biotransformation pathway and main metabolite structure; 3. To investigate the distribution of total radioactivity in whole blood and plasma and the pharmacokinetics of total plasma radioactivity in healthy male subjects after a single oral administration of \[14C\]HPP737. Participants will: 1. Take Investigational product once 2. Stay in the clinic about 7 days for checkups and tests 3. Report their symptoms

Conditions

  • Psoriasis

Interventions

  • HPP737Drug

    \[14C\]HPP737 oral preparation, 20mg(150μCi), once

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax (peak concentration)Time frame: Up to 12 months
  2. Tmax (peak time)Time frame: Up to 12 months
  3. AUC0-T (area under drug time curve)Time frame: Up to 12 months
  4. AUC0-∞ (area under drug time curve)Time frame: Up to 12 months
  5. t1/2 (elimination half-life)Time frame: Up to 12 months
  6. CL/F (apparent clearance)Time frame: Up to 12 months
  7. Vd/F (apparent volume of distribution)Time frame: Up to 12 months
  8. MRT (mean residence time)Time frame: Up to 12 months
  9. Cumulative drug excretion(Urine)Time frame: Up to 12 months
  10. Cumulative drug excretion(stool)Time frame: Up to 12 months
  11. Major metaboliteTime frame: Up to 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.